Press Releases

• March 2021

TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend”) today announced that it has entered into a securities purchase agreement with Digital Power Lending, LLC (“DPL”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“AGH”), a related party. Pursuant to the securities purchase agreement, DPL agreed to invest an aggregate of $10,000,000 in our common stock and warrants. DPL funded $4,000,000 in connection with the execution of the securities purchase agreement and will fund the balance upon Alzamend achieving certain milestones related to the U.S.

• December 2020

TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend” or the “Company”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”). The public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities,

• November 2020

Tampa. FL – (Business Newswire – November 16, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director. The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.

• November 2020

Tampa. FL – (Business Newswire – November 3, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) announced today that the Company will host a conference call and webcast led by its Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Company’s CEO and Director, on Tuesday, November 17th at 5:00pm ET (2:00pm PT). The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.

• October 2020

Tampa, FL, October 27, 2020 – Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer’s Association. Currently, Amyloid-β buildup in the brain is believed to be the cause of Alzheimer’s among many researchers. There have been many attempts to prevent or reverse the disease by targeting Amyloid-β including the first vaccine clinical trial as AN-1792 in 2002 by Elan, which targeted Amyloid-β proteins. Unfortunately,

• July 2019

Company Selects Innovative Researcher and Leader, Associate Director of DIAN-TU

Tampa, FL – (Business Newswire – July 16, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board. Dr. McDade, an innovative researcher and leader since 2010, has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research program that focuses on using brain imaging and cerebrospinal fluid markers to identify those at risk for Alzheimer disease (“AD”).

• July 2019

Tampa, FL – (Business Newswire – July 12, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that its senior management team led by Stephan Jackman, the Company’s CEO and Ken Cragun, the Company’s CFO will be participating in the annual Alzheimer’s Association International Conference® being held in Los Angeles, CA from July 12 through July 18, 2019 at the L.A. Convention Center. Also attending will be the Company’s Executive Chairman, Milton “Todd” Ault,

• July 2019

Appoints Dr. Thomas Wisniewski, Leading Pioneer in Alzheimer’s Disease

Tampa, FL – (Business Newswire – July 9, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed its first member to its Scientific Advisory Board, Dr. Thomas Wisniewski, a leading and acclaimed pioneer in the study and treatment of Alzheimer’s Disease. Dr. Wisniewski is a board-certified neurologist and neuropathologist and is the Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment who operates an active research laboratory focusing on neurodegenerative disorders with a particular focus on the mechanisms that drive amyloid deposition in Alzheimer’s and prion diseases.

• December 2018

Appoints Financial Executive, Kenneth S. Cragun, as New CFO and Treasurer

Tampa, FL – (Globe Newswire – December 26, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its new Chief Financial Officer (CFO) and Treasurer. Mr. Cragun will report directly to the Company’s Board of Directors. The selection of Mr. Cragun fulfills the Company’s goal of building a robust management team of accomplished professionals to lead the Company into 2019 and to the next level.

• November 2018

 

Salt Lake City, UT – (Globe Newswire – November 19, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a full-time proven industry leader to move the Company to the next level. Mr. Jackman has over twenty years of multi-industry experience in administration,